NASDAQ:AVTX Avalo Therapeutics (AVTX) Stock Price, News & Analysis $14.60 -0.39 (-2.60%) Closing price 04:00 PM EasternExtended Trading$14.60 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Avalo Therapeutics Stock (NASDAQ:AVTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Avalo Therapeutics alerts:Sign Up Key Stats Today's Range$14.39▼$15.0950-Day Range$14.60▼$20.7552-Week Range$12.51▼$24.27Volume736,748 shsAverage Volume1.16 million shsMarket Capitalization$783.00 millionP/E RatioN/ADividend YieldN/APrice Target$45.10Consensus RatingModerate Buy Company Overview Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company’s research strategy centers on addressing conditions in which abnormal immune-system activity contributes to inflammation and tissue damage. Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to neutralize interleukin-1 beta, a pro-inflammatory cytokine involved in several inflammatory disorders. The company is evaluating AVTX-009 in clinical development for hidradenitis suppurativa, a chronic inflammatory skin condition, and may pursue additional indications in which interleukin-1 beta plays a role. The company was formerly known as Cerecor Inc. and adopted the Avalo Therapeutics name as it shifted its strategic focus toward immunology and inflammation. Avalo is headquartered in Rockville, Maryland, and operates primarily as a research and development organization. Its products remain in clinical development and are not broadly marketed commercial therapies.AI Generated. May Contain Errors. Read More Avalo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreAVTX MarketRank™: Avalo Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 522nd out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingAvalo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on no strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAvalo Therapeutics has a consensus price target of $45.10, representing about 208.9% upside from its current price of $14.60.Amount of Analyst CoverageAvalo Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Avalo Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Avalo Therapeutics are expected to grow in the coming year, from ($2.82) to ($2.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avalo Therapeutics is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avalo Therapeutics is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvalo Therapeutics has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avalo Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.23% of the float of Avalo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvalo Therapeutics has a short interest ratio ("days to cover") of 13.24, which indicates bearish sentiment.Change versus previous monthShort interest in Avalo Therapeutics has recently increased by 4.35%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvalo Therapeutics does not currently pay a dividend.Dividend GrowthAvalo Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.11 News SentimentAvalo Therapeutics has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Avalo Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for AVTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Avalo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $415,434.00 in company stock.Percentage Held by Insiders4.46% of the stock of Avalo Therapeutics is held by insiders.Percentage Held by Institutions87.06% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avalo Therapeutics' insider trading history. Receive AVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVTX Stock News HeadlinesCritical Survey: Avalo Therapeutics (NASDAQ:AVTX) vs. SAB Biotherapeutics (NASDAQ:SABS)October 1, 2026 | americanbankingnews.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsOctober 1, 2026 | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 5 at 1:00 AM | Chaikin Analytics (Ad)Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)September 29, 2026 | globenewswire.comAvalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 CongressSeptember 23, 2026 | globenewswire.comInsider Selling: Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $202,394.02 in StockSeptember 19, 2026 | insidertrades.comAvalo Therapeutics (NASDAQ:AVTX) CFO Christopher Ryan Sullivan Sells 10,185 Shares of StockSeptember 12, 2026 | insidertrades.comAvalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)September 4, 2026 | globenewswire.comSee More Headlines AVTX Stock Analysis - Frequently Asked Questions How have AVTX shares performed this year? Avalo Therapeutics' stock was trading at $18.16 at the start of the year. Since then, AVTX stock has decreased by 19.6% and is now trading at $14.60. How were Avalo Therapeutics' earnings last quarter? Avalo Therapeutics, Inc. (NASDAQ:AVTX) released its earnings results on Thursday, August, 6th. The company reported ($0.83) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $0.25. When did Avalo Therapeutics' stock split? Avalo Therapeutics's stock reverse split on the morning of Friday, December 29th 2023.The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How do I buy shares of Avalo Therapeutics? Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avalo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avalo Therapeutics investors own include Sangamo Therapeutics (SGMO), FuelCell Energy (FCEL), Canoo (GOEV), Aurora Cannabis (ACB), Agenus (AGEN), Meta Platforms (META) and Geron (GERN). Company Calendar Last Earnings8/06/2026Today10/05/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 AVTX's financial health is in the Green zone, according to TradeSmith. AVTX has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AVTX CIK1534120 Webwww.avalotx.com Phone(410) 522-8707FaxN/AEmployees33Year Founded2015Price Target and Rating Average Price Target for Avalo Therapeutics$45.10 High Price Target$60.00 Low Price Target$30.00 Potential Upside/Downside+208.9%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($4.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$78.26 million Net MarginsN/A Pretax Margin-169,766.09% Return on Equity-58.03% Return on Assets-48.22% Debt Debt-to-Equity RatioN/A Current Ratio19.31 Quick Ratio19.31 Sales & Book Value Annual Sales$60 thousand Price / Sales13,049.97 Cash FlowN/A Price / Cash FlowN/A Book Value$4.49 per share Price / Book3.25Miscellaneous Outstanding Shares53,630,000Free Float51,238,000Market Cap$783.00 million OptionableNot Optionable Beta0.68 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:AVTX) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
